HUTCHMED announced that the US FDA granted Orphan Drug Designation to sovleplenib for treating autoimmune hemolytic anemia (AIHA). This designation offers benefits like 7 years of market exclusivity and tax credits upon approval, enhancing the drug's development prospects. Sovleplenib, a selective oral Syk inhibitor, already holds a similar designation for primary immune thrombocytopenia. Regulatory reviews for sovleplenib in China are ongoing, supported by positive clinical trial data. This status highlights the potential of sovleplenib to address rare autoimmune diseases with significant unmet medical needs.
HUTCHMED's sovleplenib gains US FDA Orphan Drug Designation, a status offering 7 years of market exclusivity and tax credits upon approval. For readers following the health sector, here is Pluang's market snapshot as of Nov 05, 2026 06:21 WIB: out of 150 priced US health stocks, 117 rose and 33 fell. Notable movers include ADMA Biologics Inc (ADMA) up 20.97% at USD 13.44 with 100% sell orders, Medline Inc. Class A (MDLN) up 18.19% at USD 40.29 with 54% sell orders, and AdaptHealth Corp (AHCO) up 16.56% at USD 7.32 with 82% sell orders.
The global polypropylene market is projected to grow from 102.7 million tons in 2026 to 139.2 million tons by 2032, with a CAGR of 5.14%. Growth is fueled by rising demand for lightweight automotive parts, mono-material flexible packaging, and high-m...
At the 2026 Chery International User Summit, Chery Auto showcased its new physical AI technology built on decades of automotive safety data and engineering. Their CheryMind AI model and CHERY All-World Engine support autonomous robots, robotaxis, and...
NOVAGOLD shareholders approved a transaction for New NOVAGOLD to acquire the remaining 40% interest in the Donlin Gold project from Paulson Advisers, increasing NOVAGOLD's ownership from 60% to 100%. This consolidation makes New NOVAGOLD the ultimate...
Fox Factory Holding Corp. has appointed Troy Henige as its new Chief Technology Officer (CTO) to lead the company's technology vision, strategy, and product roadmap. This new role aims to enhance innovation, connect engineering strengths across the c...
3M Company has reached a historic $7.35 billion settlement to resolve personal injury claims related to exposure to PFAS, toxic chemicals known as "forever chemicals." The settlement covers about 99% of existing claims, potentially benefiting 115,000...
